Verona Pharma to present Phase II data with pMDI for COPD patients
pharmafile | October 13, 2021 | News story | Research and Development |
Clinical-stage biopharmaceutical company, Verona Pharma plc (Verona), is due to present Phase II data demonstrating the positive effect of a pressurised metred-dose inhaler (pMDI) formulation of ensifentrine, in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
These data will be presented at CHEST 2021, which takes place between 17 and 20 October.
Data from Part B of the two-part study was first reported on 2 February, 2021, and this showed ensifentrine, delivered by pMDI over one week, provided statistically significant, clinically meaningful, and dose-dependent improvements in lung function. It has been well tolerated in clinical trials involving more than 1,300 subjects to date, with an adverse advent profile similar to placebo.
COPD describes a group of progressive lung diseases which is characterised by long-term respiratory symptoms and airflow limitation. Two of the most common lung conditions are chronic bronchitis and emphysema. These diseases can affect quality of life in patients sufering from it, as daily activities such as walking and dressing oneself may become more difficult.
Ensifentrine is an investigational, first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4. Veron Pharma is now conducting a global Phase III programme to evaluate ensifentrine for the treatment of COPD, with top-line results expected in 2022.
Veron Pharma is focused on developing and commercialising innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If their product candidate, ensifentrine, receives market approval, it has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound.
Lina Adams
